TransCode Therapeutics, Inc.
RNAZ • NASDAQ • Stock Fundamentals
TransCode Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Philippe Calais, with a market cap of $5.4M.
Market Cap$5.4M
Employees10.0
CEOPhilippe Calais
CountryUnited States of America
Healthcare
Biotechnology
Most Recent EarningsMay 15, 2026 · 0 months 30 days agoQ1 2026
View reportNext EarningsAug 18, 2026 · in 2 monthsQ2 2026
Financials
Based on Q1 2026 filing
TransCode Therapeutics, Inc. FAQ
Common questions about TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. (RNAZ) has a market capitalization of $5.4M and trades on NASDAQ.
TransCode Therapeutics, Inc. has approximately 10 employees.